Biotech Platforms

Sector thesis

Biotech platforms are companies that build the tools, data systems, and foundational technologies that other drug makers use to discover and develop medicines. Think of them as the infrastructure layer—they don't necessarily make the final pill, but they provide the software, lab equipment, or genetic databases that speed up the process. Why now? The megatrend is simple: drug discovery is becoming a data and computing problem, not just a chemistry problem. As genomics gets cheaper and AI gets smarter, companies that own the platforms—the databases, the analysis tools, the automation—become bottlenecks. Every biotech company needs them. That creates recurring revenue and network effects that pure drug makers don't have. The sector breaks into three main buckets. First, genomics and sequencing platforms—companies that help read and interpret DNA. Second, drug discovery software and AI tools—systems that predict which molecules will work before you test them in the lab. Third, lab automation and data infrastructure—the physical and digital systems that run experiments faster and cheaper. The biggest risk is that this sector is capital-intensive and long-cycle. A platform company might spend years building something before customers adopt it. If adoption stalls or a competitor's tool works better, the stock can crater. Also, many of these companies are unprofitable and rely on venture funding or partnerships—if biotech funding dries up, they suffer. For a retail portfolio, biotech platforms fit as a growth holding if you believe in the long-term shift toward data-driven medicine. They're less volatile than single-drug bets but more volatile than big pharma. Watch for: customer wins (which companies are actually using the platform?), cash burn rate (how long until profitability?), and partnership announcements (validation from larger players). This is a 5-10 year thesis, not a quick trade.